Compare BTMD & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTMD | PYPD |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 86.6M |
| IPO Year | 2021 | 2014 |
| Metric | BTMD | PYPD |
|---|---|---|
| Price | $2.17 | $4.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.83 | ★ $12.25 |
| AVG Volume (30 Days) | ★ 199.3K | 41.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $192,219,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $2.84 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $2.44 |
| 52 Week High | $4.75 | $5.12 |
| Indicator | BTMD | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 58.16 | 45.31 |
| Support Level | $2.02 | $4.29 |
| Resistance Level | $2.20 | $5.05 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 54.15 | 19.23 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.